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Objective: The management of patient
affected by premature ejaculation (PE) is
nowadays not highly satisfactory. Here, we aimed to evaluate
the tolerability and efficacy of a combination of tryptophan,
Satureja montana, Tribulus terrestris, Phyllanthus emblica
extracts in order to improve sexual quality of life in patients
with premature ejaculation.
Materials and methods: All patients attending to 5 urological
centers from January 2015 to March 2015, due to premature
ejaculation were enrolled in this study. At the enrolment
visit, all subjects underwent self-administered IIEF-5, Male
Sexual Health Questionnaire-Ejaculation Disorder (MSHQ-
EjD), PEDT and IELTS (calculated as mean from that per-
ceived by partner and that perceived by patient) and under-
went urological visit and laboratory examinations. All
patients received one tablet per day of a combination of tryp-
tophan, Satureja montana, Tribulus terrestris, Phyllanthus
emblica extracts for 3 months (Group A). After 3 months all
patients underwent follow-up visit with the same investiga-
tions that have been carried out in the enrolment visit. The
results were compared with a cohort of patients enrolled in
the same period in another urological center and considered
as a control group (Group B). All patients in the control
group underwent counseling and sexual behavioral treat-
ment without any pharmacological compound.
Results: At the follow-up analysis, significant changes in
terms of IELT in the Group A (mean difference: 31.90; p <
0.05) at 3 months and versus Group B at the intergroup
analysis (mean difference: 30.30; p < 0.05) were reported. In
the group A, significant differences from baseline to last fol-
low-up were observed relative to IIEF-5 (mean difference:
1.04; p < 0.05), PEDT (mean difference: -2.57; p < 0.05) and
FSH (mean difference: -16.46; p < 0.05).
Conclusion: In conclusion, patients affected by PE may signif-
icantly benefit from oral therapy with a combination of tryp-
tophan, Satureja montana, Tribulus terrestris, Phyllanthus
emblica extracts in terms of IELT and PEDT scores improve-
ment.
KEY WORDS: Premature ejaculation; Erectile dysfunction;
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INTRODUCTION
Over the past 30 years, the premature ejaculation (PE)
treatment paradigm, which previously limited to behav-
ioral psychotherapy, has expanded to include drug treat-
ment (1). Dapoxetine (Priligy, Johnson & Johnson, New
Brunswick, NJ) is the first and the only product licensed
for the treatment of PE in men aged 18-64 years, and it
belongs to a class of drugs called selective serotonin reup-
take inhibitors (SSRIs), which are frequently used to treat
depression (2-4). Across trials, receiving dapoxetine 30
and 60 mg were well tolerated with a low incidence of
adverse events (AEs) (2). The most common AEs were
those typically accompanied with SSRIs agents, and the
symptoms were mild (2). Furthermore, although treat-
ment with marketed SSRIs had been associated with sex-
ual dysfunctions and suicide attempts, there were no
reports on sexual dysfunctions or suicide events as well as
suicide attempts in these 5 RCTs (5-6). However, there
were limited available data about using dapoxetine for a
long time. Phytotherapeutics should be an interesting
option because of their generally low side effects and high
acceptance by the patients. We focused our attention on
some compounds that may be useful for the treatment of
PE. Tryptophan is an interesting phytotherapeutic com-
pound. 5-Hydroxytryptophan (5-HTP) is the intermedi-
ate metabolite of the essential amino acid L-tryptophan in
the biosynthesis of serotonin (7-8). The role of serotonin
in the ejaculation control is well known and the well
demonstrated (9-10). Moreover, 5-HTP is well absorbed
from an oral dose, with about 70% was found in the
bloodstream (11). Furthermore, 5-HT showed a good
pharmacological profile with good efficacy and appeared
to be better tolerated than SSRIs (12). On the other hand,
Satureja montana (winter savory) is a medicinal plant tra-
ditionally used to treat different disorders including male
sexual dysfunction (13). Recently, Zavatti et al. found that
Satureja montana is able to delay ejaculation latency with-
out exerting any negative effect on the other parameters
of sexual behavior and without exerting a sedative effect
(13). Finally, the role of Phyllanthus emblica. Chebulagic
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acid, the major constituent of Phyllanthus emblica, is a
benzopyran tannin compound with various kinds of
medicinal potentials including improvement of male sex-
ual dysfunction (14-15). In fact, Chebulagic acid is able
to inhibit Rho-kinase 2 and may be useful in management
of erectile dysfunction (14). Here, we aim to evaluate the
tolerability and efficacy of a combination of tryptophan,
Satureja montana, Tribulus terrestris, Phyllanthus embli-
ca extracts (EIACUMEV®) in order to improve sexual
quality of life in patients with premature ejaculation.
PATIENTS AND METHODS
Study design
All patients attending to 5 urological centers from January
2015 to March 2015, due to premature ejaculation were
enrolled in this study. At the enrolment visit, all subjects
underwent self-administered IIEF-5, Male Sexual Health
Questionnaire-Ejaculation Disorder (MSHQ-EjD), PEDT
and IELTS and underwent urological visit and laboratory
examinations. The IELT has been calculated as mean from
that perceived by partner (PPIELT) and that perceived by
patient (IELT). All patients underwent preliminary assess-
ment including a detailed medical and sexual history to
evaluate the presence of underlined risk factors such as
infections or diabetes mellitus. All patients received one
tablet per day of a combination of tryptophan, Satureja
montana, Tribulus terrestris, Phyllanthus emblica extracts
for 3 months (Group A). After 3 months all patients
underwent follow-up visit with the same investigations
that have been carried out in the enrolment visit. The
results were compared with a cohort of patients enrolled
in the same period in another urological center and con-
sidered as a control group (Group B). All patients in the
control group underwent counseling and sexual behav-
ioral treatment without any pharmacological compound.
All subjects gave written informed consent before entering
the study, which was conducted in accordance with the
Declaration of Helsinki. 
Inclusion and exclusion criteria
The primary inclusion criteria were age ≥ 18 years of age
and in a stable monogamous relationship for ≥ 6 months
were eligible if they met the DSM-IV-TR criteria for PE
for ≥ 6 months, indicated at least moderate PE-related
distress or interpersonal difficulty, and reported an IELT
of ≤ 2 min in ≥ 75% of evaluable events during a 4-wk
screening/baseline period. Exclusion criteria were as fol-
lows: any medical treatment for sexual dysfunction
before or during the study, congenital or acquired penile
curvature or chordee with hypospadias, age > 75 years,
hypogonadism (total testosterone level < 8 nmol or
serum testosterone in the range of 8-11 nM and free
testosterone < 220 pmol, assessed at least on two occa-
sions). To be able to exclude organic sexual dysfunctions
and other underlying illnesses, fasting blood glucose
level, urinalysis, complete blood count, sex hormones,
and prolactin levels were measured. All measurements
were conducted by a single physician unaware of the
treatment status. Moreover, all patients with erectile dys-
function (a reported IIEF-15-EFD score ≤ 21) were
excluded, as suggested by Salonia (16).
Questionnaires and urological examinations 
Sexual health was evaluated using available validated
instruments for the study of erectile function (Inter -
national Index of Erectile Function-15 erectile function
domain [IIEF-15-EFD]) (17) and ejaculatory status
(PEDT) (18). In order to exclude all patients with life-
long PE, a careful urological visit with disease history
collection has been performed at the arrival at each
Centre, as suggested by Jannini et al. (19). Moreover, the
Male Sexual Health Questionnaire-Ejaculation Disorder
(MSHQ-EjD) was also used to evaluate the ejaculation
function (20). 
Assignment to the groups
All patients were assigned to each group on the basis of
the attending center. All patients attending to 5 centers
(Rome 2 centers, Catania, Florence, Catanzaro) were
assigned to Group A, while all patients attending anoth-
er center (Trento) were assigned to Group B (controls).
The study design is displayed in Figure 1.
Group A
The first group received one tablet orally a day for 3
months and one tablet consisted of 300 mg of Satureya
Figure 1. 
The figure
shows the
study design
schedule.
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montana, Tribulus terrestris, Phyllanthus emblica,
Cardamomo, L-tryptophan, ascorbic acid, vitamin PP, vita-
min B1, vitamin B6 (EiacuMev®, Farmaceutica MEV, Siena,
Italy). We monitored adverse events on the light of com-
mon terminology criteria for adverse events (CTCAE)
guidelines. Safety assessments included treatment-emer-
gent adverse events (TEAEs), serious AEs (SAEs), and
orthostatic vital signs (blood pressure and heart rate).
Group B
All patients in the control group underwent counseling
and sexual behavioral treatment without any pharmaco-
logical compound. The counseling and sexual behavioral
treatment has been carried out in collaboration with a
dedicated psychologist, as commonly in our routinely
clinical practice. The sexual counseling and psychother-
apy has been performed in line with the suggestions of
Rowland and Cooper (21).
Main outcome measures
The primary end point was stopwatch-measured IELT
(held by the partner), reported for each intercourse
episode. Secondary outcomes were the change from
baseline to end point of MSHQ-EjD, IIEF-5 and PEDT.
Statistical analysis and study population
As null hypothesis, we assumed there would be no dif-
ference in terms of mean IELT score, between the two
groups. A sample size of 60 subjects per treatment group
provided 90% power (two-sided α = 0.05), to detect a 30
seconds difference in mean IELT between patients and
controls. The maximum sample size was set to 70 sub-
jects per group, allowing for a 15% dropout rate. At
baseline, the independent sample 2-tailed t-test was used
to compare variables. For categorical parameters, chi-
square test was applied. Changes from baseline to end of
therapy were analyzed using ranked one-way analysis of
variance (ANOVA) with a term for treatment group.
Data were reported as means ± standard deviation (SD).
For all statistical comparisons, significance was consid-
ered as p < 0.05. All reported p-values are two-sided. All
statistical analyses were performed by using SPSS 11.0
for Apple-Macintosh (SPSS, Inc., Chicago, Illinois).
RESULTS
One hundred and seventy patients were enrolled. Forty-
two patients were excluded and 128 patients were final-
ly randomized, 63 and 65 subjects in the group A and in
the group B completed the study protocol. The flow
chart of this study is presented in Figure 2.
Baseline characteristics 
All anamnestic, clinical, and questionnaires characteris-
tics of all enrolled patient are displayed in Table 1.
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Group A Group B
No. of patients 63 65
Age (yr), mean ± SD 32.03 ± 8.68 35.37 ± 8.81
BMI (Kg/m2), mean ± SD 26.36 ± 3.0 25.2 ± 3.5
LH, mean ± SD 87.96 ± 56.92 86.76 ± 55.43
FSH, mean ± SD 57.00 ± 37.29 54.61 ± 35.70
Total testosterone, mean 6.89 ± 3.87 7.01 ± 3.02
Smoking habit, n (%) 25 (39.68) 26 (36.92)
IIEF-5, mean ± SD 27.31 ± 2.86 27.71 ± 3.77
PEDT, mean ± SD 13.82 ± 2.79 14.05 ± 2.54
IELT (sec), mean ± SD 54 ± 17.76 52 ± 18.82
EjQ, mean ± SD  14.89 ± 1.07 15.01 ± 1.35
PSV, mean ± SD 31.52 ± 6.60 30.02 ± 5.56
EDV, mean ± SD 1.5 ± 1.0 1.2 ± 2.0
BMI = Body Mass Index; IIEF-EF = International Index of Erectile Function-Erectile 
Function; IIEF-IS =  International Index of Erectile Function-Intercourse Satisfaction; IIEF-
OF = International Index of Erectile Function-Orgasmic Function; IIEF-SD = International
Index of Erectile Function-Sexual Desire; IIEF-OS = International Index of Erectile
Function-Overall Satisfaction; MSHS-EJD = Male Sexual Health Questionnaire-
Ejaculation Disorder; SQoL-M = Sexual Quality of life instrument for Men; PSV = peak
systolic velocity; EDV = end diastolic velocity.
Table 1. 
Baseline characteristics of patients enrolled.
Figure 2. 
The figure shows the study
flow chart in accordance to
the CONSORT guidelines.
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Follow-up examination
The Table 2 lists the mean change differences from base-
line to 3 months relative to main outcome measures.
When concerning the primary endpoint of this study, we
observed significant changes of the IIELT in the Group A
(mean difference: 31.90; p < 0.05) at 3 months and ver-
sus Group B at the intergroup analysis (mean difference:
30.30; p < 0.05). In the group A, significant differences
from baseline to last follow-up were observed relative to
IIEF-5 (mean difference: 1.04; p < 0.05), PEDT (mean
difference: -2.57; p < 0.05) and FSH (mean difference: 
-16.46; p < 0.05). 
Significant differences were found at the intergroup
analysis when considering previous outcome measures
(Table 2; Figure 3). 
When considering serum TT and MSH-EjD, both groups
did not show any difference after 3 months.
Adverse events
All subjects included in the study protocol, tolerated the
treatments and none reported adverse events.
DISCUSSION
Even if PE is one of the most common sexual dysfunc-
tions among young male patients and in spite of the
increasing interest in PE in the field of sexual medicine, a
highly satisfactory treatment in terms of efficacy and safe-
ty is still needing (22). For these reasons, even if the pre-
ferred management of PE is on-demand Dapoxetine,
many urologists used other treatment options in 35% of
the initial treatment cases and 50% of the second-line
treatment cases (23). Here, we demonstrated that the use
of tryptophan, Satureja montana, Tribulus terrestris,
Phyllanthus emblica extracts is able to improve the
patient’s ejaculatory control, with a higher IELT and high-
er level of quality of life. Moreover, we demonstrated a
high level of treatment compliance, probably due to the
low frequency of adverse events and the efficacy of the
treatment in terms of ejaculatory control improvement. 
The results of our study are probably due to synergic effi-
cacy of Satureja montana and tryptophan. It is really dif-
Group A Group B
LH, mean ± SD 12.72 ± 60.07 10.50 ± 55.00
FSH, mean ± SD -16.46 ± 37.42 a, b 2.52 ± 5.76
Total testosterone, mean 1.55 ± 10.93 1.23 ± 9.81
IIEF-5, mean ± SD 1.04 ± 1.67 a 0.31 ± 0.87
PEDT, mean ± SD -2.57 ± 2.38 a, b -1.03 ± 2.45
IELT (sec), mean ± SD 31.90 ± 45.68 a, b 1.60 ± 9.81
EjQ, mean ± SD  -0.015 ± 0.65 0.02 ± 0.89
a p < 0.05 vs. baseline; b p < 0.05 vs. Group B.
Table 2. 
Mean changes from baseline to 3 months for primary 
and secondary outcomes.
Figure 3. 
The figure shows the
significant differences
found at the intergroup
analysis (Group A)
when considering
outcome measures.
V0: enrolment time;
V1: follow-up visit 
(at 3 months from the
treatment starting).
IIEF-EF = International
Index of Erectile
Function-Erectile
Function; MSHS-EJD =
Male Sexual Health
Questionnaire-
Ejaculation Disorder;
PEDT = premature
ejaculation diagnostic
tool; IELTS =
Intravaginal Ejaculatory
Latency Time:
calculated as mean
form partner and
patient perceived IELT.
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ficult to evaluate the efficacy of each single compound on
the PE improvement. 
Several Authors demonstrated that serotonin may be
associated with physical health as well as mood (24) and,
in particular, in healthy people with high trait irritability,
tryptophan, relative to placebo, decreased quarrelsome
behaviors, increased agreeable behaviors and improved
mood (25). 
Nonpharmacologic methods of raising brain serotonin
may not only improve mood, social functioning of
healthy people, but would also improve sexual quality of
life, improving the ejaculatory control. 
5-hydroxytryptophan is the immediate precursor to
serotonin and, by acting on 5-HT1A cerebral autorecep-
tors, spinal 5-HT1B and 5-HT2C receptors, has a deter-
mining role on ejaculation. 
On the other hand, Zavatti et al. demonstrated that that
the acute administration of Satureja montana extract is
able to significantly increase the ejaculation latency and
reduced the number of intromissions before ejaculation,
without affecting the percentage of animals achieving
ejaculation (100% in all experimental groups) (13). They
hypothesized that the efficacy of Satureja montana on
premature ejaculation is due to its impact on male sexu-
al behavior (13). However, even if the plants belonging
to the genus Satureja are traditionally known as aphro-
disiac remedy, no study was performed to confirm this
property (13, 26). However, even if our results are prom-
ising, this study shows several limitations to take into
account. 
Firstly, the number of enrolled patients. Even if the num-
ber need to treat is correctly calculated is very important
to highlight that the safety of phytotherapy should be
evaluated with a long-term follow-up, in order to dis-
cover delayed adverse side effects. Moreover, the lack of
a long-term follow-up in order to evaluate the long-term
efficacy of this compound.
CONCLUSION
In our study, we demonstrated that patients affected by
PE may significantly benefit from oral therapy with tryp-
tophan, Satureja montana, Tribulus terrestris,
Phyllanthus emblica extracts  by improving IELT, PEDT
and slightly IIEF-5.
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